SCHEMBL6983882

SCHEMBL6983882

CCOC(=O)CN(c1ccc2ncccc2c1)S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
USP2 O75604 2/20 0.48
MAPK1 P28482 1/20 0.48
NR1I2 O75469 1/20 0.47
TSHR P16473 1/20 0.47
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 1/20 0.43
KEAP1 Q14145 3/20 0.43
NFE2L2 Q16236 3/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
NAMPT P43490 1/20 0.43
BCAT1 P54687 1/20 0.43
HCRTR2 O43614 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6983887 0.80 HTT (0.53) ALDH1A1TSHRLMNASMN1; SMN2KDM4E
SCHEMBL1040305 0.78 HCRTR2 (0.64) ALDH1A1KEAP1NFE2L2HCRTR2
SCHEMBL7423210 0.77 ALDH1A1 (0.55) ALDH1A1USP2MAPK1NR1I2TSHR
SCHEMBL1038672 0.77 HCRTR2 (0.55) ALDH1A1KEAP1NFE2L2HCRTR2
SCHEMBL1039268 0.77 KEAP1 (0.55) KEAP1NFE2L2HCRTR2
SCHEMBL7956823 0.75 NR1I2 (0.55) ALDH1A1NR1I2SMN1; SMN2RAB9AKDM4E
SCHEMBL1040980 0.75 HCRTR2 (0.57) ALDH1A1KEAP1NFE2L2HCRTR2
SCHEMBL1040995 0.75 HCRTR2 (0.48) KEAP1NFE2L2HCRTR2
SCHEMBL6984894 0.74 L3MBTL1 (0.56) ALDH1A1NR1I2LMNASMN1; SMN2RAB9A
SCHEMBL27849029 0.74 HPGD (0.72) USP2LMNAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed